This research investigates a new targeted treatment strategy for kidney cancer by inhibiting the cancer-promoting protein PIM1 while enhancing TRAIL-mediated apoptosis. Together with the FDA-approved drug ONC201, this combination restores cancer cells' ability to self-destruct, offering a promising therapeutic approach now being evaluated in preclinical studies.

This research explores how early-life stress alters the gut microbiome and its communication with the brain, challenging the traditional "leaky gut" theory of anxiety. Using a comprehensive, lifespan-wide approach, it identifies a potential new mechanism that could enable more personalized treatments for patients who do not respond to current anxiety therapies.

This research identifies UCH-L1 as a promising blood biomarker directly linked to human eggs, offering a new way to measure ovarian reserve. A simple blood test could improve fertility assessment, detect premature ovarian aging earlier, and provide valuable insights into broader aspects of women's health, including cardiovascular health, cognitive aging, and longevity.

This research develops hybrid lipo-polymeric nanoparticles that overcome major limitations of current mRNA vaccine technology. The particles can be freeze-dried, rapidly loaded with mRNA, and simultaneously deliver therapeutic drugs. Their flexibility improves vaccine storage and distribution while enabling powerful combination therapies, including enhanced cancer treatments with improved survival in preclinical models.

This research develops an affordable, scalable platform for recording electrical activity from brain organoids. Using innovative basket-shaped sensors made from a low-cost conductive material, the system enables simultaneous recording from dozens of mini-brains, accelerating drug discovery and improving our understanding of brain diseases with more human-relevant laboratory models.

This research engineers DNA-modified exosomes to deliver drugs precisely to cancer cells while avoiding healthy tissue. By disguising natural cell-targeting signals and adding programmable DNA targeting molecules, the platform could reduce treatment side effects and provide a modular delivery system adaptable to many cancers and other diseases.

This research has developed a five-minute smartphone memory test that detects subtle cognitive changes associated with early Alzheimer's disease. The tool identified symptom-free individuals with underlying disease and predicted future cognitive decline, outperforming expensive brain scans while offering a simple, accessible, and affordable approach to early diagnosis.

This research investigates how aging changes blood stem cells, causing them to produce excess sticky platelets that increase the risk of heart attack and stroke. By identifying the genetic mechanisms behind this age-related shortcut, the work aims to develop therapies that reduce cardiovascular disease while improving healing in patients with low platelet counts.

This research developed NanoX, a nanoscale fluorescent sensor that images oxytocin release from individual neurons in real time. By revealing patterns of brain chemistry associated with mental health disorders, the technology could enable earlier diagnosis, improve understanding of neurochemical signaling, and support both preventive and personalized mental healthcare.

This research engineers peptide-based "drug cages" that assemble like molecular zippers to deliver medicines only at their intended target. Inspired by natural protein structures, these programmable nanostructures could dramatically reduce chemotherapy side effects by releasing drugs precisely where needed, improving treatment effectiveness while protecting healthy tissues.